Latest Södertälje Municipality Stories
SOUTH SAN FRANCISCO, Calif., June 17, 2013 /PRNewswire/ -- NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell (EEC) program for the treatment of type 2 diabetes and obesity. EECs represent less than 1% of all gastrointestinal (GI) cells, but produce virtually all of the...
Innovative integrated technology approach aims to link partners seamlessly to improve efficiency and management of clinical studies CONSHOHOCKEN, Pa., June 10, 2013 /PRNewswire/ -- ePharmaSolutions, a leading clinical services and eClinical solutions provider, has signed a deal with AstraZeneca Neuroscience Innovative Medicines (AZ NS iMed), to provide IT solutions that will enable the iMed to share and manage complex data on a common portal with clinical trial investigators and...
CARLSBAD, Calif., June 6, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $6 million payment from AstraZeneca related to continuation of the research collaboration between Isis and AstraZeneca to discover and develop novel antisense therapeutics to treat cancer. In addition to the research collaboration, which includes three cancer targets, Isis and AstraZeneca are developing two antisense drugs, ISIS-AR(Rx) and ISIS-STAT3(Rx),...
MONTREAL, May 29, 2013 /CNW/ - NEOMED and AstraZeneca announced today the expansion of their strategic partnership, further enabling NEOMED's mission of delivering novel therapeutic solutions for unmet medical needs. AstraZeneca will provide NEOMED access to up to 250,000 high-quality compounds from its small molecule compound library to be used to identify candidate compounds for selected targets. The goal is to identify compounds that could potentially become new medicines for a...
MALVERN, Pa., March 6, 2013 /PRNewswire/ -- Michael Hickey, former Vice President of US Sales at AstraZeneca and former President of AstraZeneca, Netherlands has recently joined Delta Point, Inc. as Senior Vice President of Global Leadership Development. "Michael is a perfect fit for the future direction of Delta Point as we focus on the sales leadership required for the delivery of exceptional sales performance," explained Jerry Acuff, founder and CEO of Delta Point. "Developing the...
WELWYN GARDEN CITY, England and BOSTON, February 8, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery company, announces that its President, Dan Grau, will attend the Boston Biotech Conference New York CEO Meeting [http://bbbiotechconference.com/conference-details.php?id=13 ] taking place on 13-14 February at Apella in New York City, NY, USA, at which he will moderate a panel on Rare Diseases (3:30pm EST, 14 February). For a full list of events...
CARLSBAD, Calif., Dec. 11, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca announced today a strategic alliance for the discovery and development of novel generation antisense therapeutics against five cancer targets, which includes a license to develop and commercialise ISIS-STAT3(Rx), a drug Isis is currently evaluating in an early clinical trial in patients with advanced lymphomas. Antisense therapies target the proteins involved in disease processes...
WILMINGTON, Del., Nov. 8, 2012 /PRNewswire-USNewswire/ -- The following is being issued by the law firms of Kessler Topaz Meltzer & Check LLP, Fine, Kaplan and Black R.P.C., and Pomerantz Grossman Hufford Dahlstrom & Gross LLP. A Settlement has been reached in a class action lawsuit involving the heart medication, Toprol XL®, and its generic equivalent, metoprolol succinate. Defendants AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, and Aktiebolaget Hassle...
BERLIN, Oct. 18, 2012 /PRNewswire/ --caprotec bioanalytics GmbH announced today a restructuring of its senior management and the appointment of Dr. Jonathan Turner as Managing Director and Chief Executive Officer. Dr. Turner joins caprotec as a highly regarded pharmaceutical executive and has held a number of senior management positions at global pharmaceutical companies, including Boehringer Ingelheim, AstraZeneca PLC and Schering AG. Prof. Dr. Hubert Koester, Founder and previous...
STOCKHOLM, October 8, 2012 /PRNewswire/ -- Scania has turned to eBuilder for help with streamlining and better coordinating their travel management and travel expense accounting. On March 26 this year, eBuilder's cloud-based solution was deployed to Scania's 30 companies in Sweden. Initially, the solution encompasses only travel cost accounting, but it will successively be broadened to improve the entire travel administration process. "In our effort to streamline our...
